IMBIORAY
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases.
IMBIORAY
Industry:
Biotechnology Medical Therapeutics
Founded:
2014-01-01
Status:
Active
Total Funding:
0
Investors List
Lucky Source Funds
Lucky Source Funds investment in Venture Round - Imbioray
More informations about "Imbioray"
Imbioray - Crunchbase Company Profile & Funding
Imbioray has 6 investors including Sunzi Technology and Huayi Capital. When was the last funding round for Imbioray? Imbioray closed its last funding round …See details»
Imbioray (Hangzhou) Biomedicine Co., Ltd. - Drug …
Jul 1, 2023 Founded in 2014, Imbioray (Hangzhou) Biomedicine Co., Ltd. specializes in treatments for cancer and immune-related diseases. By 2016, the company shifted its focus towards the development of innovative, off-the-shelf …See details»
Organization | Imbioray (Hangzhou) Biomedicine Co., Ltd.
Organization Overview. First Clinical Trial. 2020 NCT05215015. First Marketed Drug. None First NDA Approval. None ... Imbioray (Hangzhou) Biomedicine Co., Ltd. Active Ingredients. Drugs …See details»
Imbioray (Hangzhou) Biomedicine - VentureRadar
Imbioray (Hangzhou) Biomedicine develops first-in-class off-the-shelf allogeneic CAR-NK and NK cell therapy programs. ... Find out more about Imbioray (Hangzhou) Biomedicine, …See details»
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in …
Apr 23, 2025 Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase II …See details»
英百瑞 - 公司详情 - 公司概况 - innoHere英诺嘿呀
杭州英百睿生物医药技术有限公司成立于2014年，聚焦肿瘤免疫治疗和免疫力疾病的治疗。2016年专注于创新型通用现货car-nk细胞疗法的开发，通过其原创的技术平台，研发出一系列细胞和抗体药物，致力于解决临床未满足的疾病，多个产 …See details»
iMBIORAY 2025 Company Profile: Valuation, Funding
IMBIORAY General Information Description. Developer of innovative drugs designed for the treatment of tumor and immune diseases. The company's drugs focus on technology in non-genetically modified CAR-NK (Chimeric antigen …See details»
Imbioray - Financial Details - Crunchbase
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. ... How much funding has this organization raised over time? Show . …See details»
iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies
Jan 23, 2025 Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by …See details»
Imbioray - Growth Outlook - Crunchbase
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. …See details»
Imbioray - Crunchbase
Organization. Imbioray . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. ... Imbioray and Neorigen Biotech share similar …See details»
Imbioray - Updates, News, Events, Signals & Triggers - Crunchbase
Feb 22, 2022 Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. New. Resources. Advanced Search. Start Free Trial . Talk …See details»
英百瑞：完成A+轮近亿元融资，加速推进CAR-NK细胞疗法医药新 …
⌈ByDrug医药新闻摘要⌋ 2025-01-22 10:53，细胞基因治疗前沿：本轮融资由在投资领域颇具影响力的华睿投资领投，泰珑投资、孙子科技、华医资本、滨江5050基金跟投。 本轮融资主要用于 …See details»
iMBioRay - 创投之家
Feb 22, 2022 英百瑞（iMBioRay）完成2.3亿元A轮融资 英百瑞（杭州）生物医药有限公司（英百瑞，iMBioRay）近日宣布完成2.3亿人民币A轮融资，本轮融资由瑞享源基金和中南创投基金 …See details»
Imbioray closes $36.3M Series A to advance CAR-NK therapy; …
Feb 22, 2022 Imbioray (Hangzhou) Biomedicine said it has completed an RMB 230 million Series A round to advance its first-in-class off-the-shelf allogeneic CAR-NK and NK cell …See details»
【隆门Family】英百瑞2024年度重大成果回顾医药新闻-ByDrug-一 …
⌈bydrug医药新闻摘要⌋ 2025-01-03 16:07，隆门资本：英百瑞（杭州）生物医药有限公司2024年度重大科研、奖项、资质及成果回顾：。 3、2024年3月，英百瑞荣获 biochina“2023创新突破企 …See details»
Imbioray completed 230 million RMB in Series A financing ... - T …
Feb 22, 2022 Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Imbioray") announced the completion of RMB 230 million in Series A financing to promote the …See details»
「最新融资」英百瑞生物：完成A+轮融资，领跑中国NK细胞治疗 …
⌈ByDrug医药新闻摘要⌋ 2025-01-21 21:27，药圈时汇：近日， 英百瑞（杭州）生物医药有限公司（以下简称“英百瑞”）完成 A+ 轮近亿元融资 。 本轮融资由在投资领域颇具影响力的 华睿投 …See details»
英百瑞 - 公司详情 - 产品&解决方案 - innoHere英诺嘿呀
杭州英百睿生物医药技术有限公司成立于2014年，聚焦肿瘤免疫治疗和免疫力疾病的治疗。2016年专注于创新型通用现货car-nk细胞疗法的开发，通过其原创的技术平台，研发出一系列细胞和 …See details»
Series A - Imbioray - 2025-01-21 - Crunchbase Funding Round …
Imbioray raised $13535130 on 2025-01-21 in Series A. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Funding Round. Series A - Imbioray . …See details»